eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2024
vol. 16
 
Share:
Send email
Share:
Original paper

Clinical efficacy of iodine-125 radioactive particle implantation with deep hyperthermia in malignant tumor treatment: A retrospective analysis

Yuting Yuan
1
,
Yunfeng Kou
1
,
Jian Yu
2
,
Shenghe Zhang
1
,
Songbai Chen
1
,
Ruoyu Wang
3
,
Zhe Wang
3
,
Jun Zhou
1
,
Chuang Li
1

  1. Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
  2. Center of Thermotherapy, Affiliated Zhongshan Hospital of Dalian University, China
  3. Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, China
J Contemp Brachytherapy 2024; 16, 3: 202–210
DOI: https://doi.org/10.5114/jcb.2024.141407
Online publish date: 2024/06/30
Article file
- Clinical efficacy of (1).pdf  [0.53 MB]
Get citation
 
 
1. Han B, Zheng R, Zeng H et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi 2024; 46: 221-231.
2. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
3. Bray F, Laversanne M, Weiderpass E et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021; 127: 3029-3030.
4. Zhan TC, Zhang DK, Gu J et al. Surgical complications after different therapeutic approaches for locally advanced rectal cancer. World J Gastrointest Oncol 2019; 11: 393-403.
5. Chabner BA, Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72.
6. Shin HS. Comments on: Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy. J Gynecol Oncol 2021; 32: e50.
7. Wang H, Wang L, Jiang Y et al. Long-term outcomes and prognostic analysis of computed tomography-guided radioactive 125I seed implantation for locally recurrent rectal cancer after external beam radiotherapy or surgery. Front Oncol 2021; 10: 540096.
8. Wang J, Chang X, Xu K et al. CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer. Front Oncol 2023; 13: 1171813.
9. Liebl CM, Kutschan S, Dörfler J et al. Systematic review about complementary medical hyperthermia in oncology. Clin Exp Med 2022; 22: 519-565.
10. Linthorst M, van Geel AN, Baaijens M et al. Re-irradiation and hyperthermia after surgery for recurrent breast cancer. Radiother Oncol 2013; 109: 188-193.
11. Issels RD, Abdel-Rahman S, Wendtner C et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 2001; 37: 1599-1608.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
13. Zhang F, Wang J, Guo J et al. Chinese Expert Consensus Workshop Report: Guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors. Thorac Cancer 2019; 10: 388-394.
14. Rivard MJ, Coursey BM, Dewerd LA et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633-674.
15. Rivard MJ. Comment on “Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group 43” [Med. Phys. 22, 209-234 (1995)]. American Association of Physicists in Medicine. Med Phys 1999; 26: 2514.
16. Wang J, Chai S, Wang R et al. Expert consensus on computed tomography-assisted three-dimensional-printed coplanar template guidance for interstitial permanent radioactive 125I seed implantation therapy. Cancer Res Ther 2019; 15: 1430-1434.
17. Cocks K, Wells JR, Johnson C et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer 2023; 178: 128-138.
18. Zhuang J, Liu Y, Xu X et al. Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma. J Cancer Surviv 2023; 17: 1769-1779.
19. Hurvitz SA, Hegg R, Chung WP et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401: 105-117.
20. Monk BJ, Tewari KS, Dubot C et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2023; 24: 392-402.
21. Farrar JT, Young JP, Jr., Lamoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-158.
22. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
23. van der Zee J, González González D, van Rhoon GC et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000; 355: 1119-1125.
24. Islami F, Ward EM, Sung H et al. Annual Report to the Nation on the Status of Cancer. Part 1: National cancer statistics. J Natl Cancer Inst 2021; 113: 1648-1669.
25. Mo Z, Zhang T, Zhang Y et al. Feasibility and clinical value of CT-guided (125)I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure. Eur Radiol 2018; 28: 1194-1203.
26. Zhongmin W, Yu L, Fenju L et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol 2010; 20: 1786-1791.
27. Dai F, Wang J, An H et al. Therapy of (125)I particles implantation inhibited the local growth of advanced non-small cell lung cancer: a retrospective clinical study. Am J Transl Res 2019; 11: 3737-3749.
28. Merten R, Ott O, Haderlein M et al. Long-term experience of chemoradiotherapy combined with deep regional hyperthermia for organ preservation in high-risk bladder cancer (Ta, Tis, T1, T2). Oncologist 2019; 24: e1341-e1350.
29. Li H, Wang M, Zhu Z et al. Application value of the treatment of breast cancer bone metastases with radioactive seed 125I implantation under CT-guidance. BMC Med Imaging 2022; 22: 3.
30. Chen G, Han M. Comparison of pre-implant treatment planning and post-implant dosimetry in I-125 spinal metastases brachytherapy. Oncol Lett 2020; 19: 309-316.
31. Zhang J, Sun Q, Gao L et al. A multicenter prospective study on quality of life and pain relief for cancer patient after (125)I seed implantation. Asia Pac J Oncol Nurs 2022; 9: 100065.
32. Jiang Y, Ji Z, Guo F et al. Side effects of CT-guided implantation of (125)I seeds for recurrent malignant tumors of the head and neck assisted by 3D printing non co-planar template. Radiat Oncol 2018; 13: 18.
33. Zhang S, Chen S, Wang R et al. Clinical efficacy and safety analysis of CT-guided (125)I implantation in the treatment of recurrent or metastatic pelvic malignant tumor. Brachytherapy 2023; 22: 132-138.
34. Schem BC, Pfeffer F, Ott MA et al. Long-term outcome in a phase II study of regional hyperthermia added to preoperative radiochemotherapy in locally advanced and recurrent rectal adenocarcinomas. Cancers (Basel) 2022; 14: 705.
35. Hildebrandt B, Wust P, Ahlers O et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33-56.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.